Coronavirus Actions: How Pharma In India Is Handling Safety, Business Continuity
Scrip contacted a cross section of pharma firms in India to get a sense of how they are handling the extraordinary work-operations-employee well-being situation amid the coronavirus outbreak. Work from home mandates, deploying digital tools wherever possible, cut-back in field activities and daily temperature checks at sites are some of the initiatives set in motion.
You may also be interested in...
OPPI Head On Sustaining Supplies In India During The Pandemic
OPPI director general and ex-MSD India chief outlines how pharma in India is ensuring medicines reach patients amid COVID-19, working closely with various stakeholders. De-risking the supply chain and up-skilling sales forces in view of widespread digital engagement are among the key issues firms are addressing.
How EFPIA Set The Bar On Drug Safety Reporting During COVID-19
Early disruptions caused by the coronavirus pandemic prompted the European pharmaceutical industry body, EFPIA, to establish a principles-based framework to help ensure consistency in managing compliance with pharmacovigilance responsibilities.
Alembic: Enough Inventory, China API Supplies Heading Back To Normalcy
Alembic says it is 'comfortably placed' in terms of inventories and is seeing improving API supplies from China. The only area of some concern is outbound logistics against a backdrop of flights being halted and population lock-downs.